drugset / Trial / NCT03602235
High Dose Ascorbic Acid for Plasma Cell Disorders
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
Timeline
- Start
- 2019-03-05
- Primary completion
- 2024-07-01
- Completion
- 2025-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 12.5 mg/m2 | — |